Отправить эту статью по почте 
МОЖЕТ ЛИ МЕЛАТОНИН ЭФФЕКТИВНО ИСПОЛЬЗОВАТЬСЯ ДЛЯ КОРРЕКЦИИ ПОБОЧНЫХ ЭФФЕКТОВ РАЗЛИЧНЫХ ПСИХОТРОПНЫХ ЛЕКАРСТВ И ЭЛЕКТРОСУДОРОЖНОЙ ТЕРАПИИ?
Аннотация
Цель исследования. Изучить и обобщить имеющуюся доказательную базу для применения мелатонина в качестве корректора побочных эффектов психотропных лекарств и электросудорожной терапии, и представить читателю соответствующие выводы.
Методология проведения работы. Авторами был проведён поиск литературы о применении мелатонина в качестве корректора побочных эффектов психотропных лекарств и электросудорожной терапии в PubMed и Google Scholar. Найденные в результате этого поиска литературные данные представлены в настоящей статье.
Результаты. Полученные нами в результате данного обзора литературы данные свидетельствуют о том, что мелатонин может быть эффективно использован как в монотерапии, так и в комбинации с другими корректорами с целью уменьшения ряда побочных эффектов психотропных лекарств и электросудорожной терапии, и заслуживает дальнейшего изучения в этом качестве. Доказательная база по его применению различна для различных побочных эффектов. Наибольшая доказательная база имеется об эффективности применения мелатонина в предотвращении и лечении диссомнических нарушений, нарушений памяти и когнитивных функций, акатизии, поздних дискинезий, а также метаболического синдрома.
Область применения результатов. Полученные нами результаты могут применяться в психиатрии, неврологии и наркологии, а также во всех тех областях общесоматической медицины, в которых находят своё применение психотропные препараты.
Ключевые слова
Полный текст:
>PDF
Литература
Беккер Р.А., Быков Ю.В. Когнитивные нарушения при депрессиях: клиническое значение и современные возможности терапии // Психиатрия и психофармакотерапия. 2015. Т. 17. №. 4. С. 40–45 (Bekker R.A., Bykov Yu.V. Psikhiatriya i psikhofarmakoterapiya. 2015. V. 17. №. 4, рр. 40–45).
Беккер Р.А., Быков Ю.В. Акатизия: клинический анализ патологии с рекомендациями и обзором литературы // Consilium Medicum. http://con-med.ru/upload/iblock/eaa/psi_akatisia2.pdf (дата обращения: 17.08. 2017) (Bekker R.A., Bykov Yu.V. Consilium Medicum. http://con-med.ru/upload/iblock/eaa/psi_akatisia2.pdf)
Быков Ю.В., Беккер Р.А. Минимизация когнитивных нарушений при электросудорожной терапии: реалии и перспективы (Обзор литературы с комментариями и рекомендациями) (I часть: Теоретическая) // В мире научных открытий. 2016. Т. 81. №. 10. С. 54–92 (Bykov Yu.V., Bekker R.A. V mire nauchnykh otkrytiy. 2016. V. 81. №. 10, рр. 54–92).
Быков Ю.В., Беккер Р.А. Минимизация когнитивных нарушений при электросудорожной терапии: реалии и перспективы (Обзор литературы с комментариями и рекомендациями) (II часть: Практическая) // В мире научных открытий. 2016. Т. 84. №. 12. С. 200–272 (Bykov Yu.V., Bekker R.A. V mire nauchnykh otkrytiy. 2016. V. 84. №. 12, рр. 200–272).
Быков Ю.В., Ханнанова А.Н., Беккер Р.А. Мелатонин и бензодиазепины в лечении инсомнии: за и против (обзор литературы) // В мире научных открытий. 2016. Т. 79. №. 7. С. 60–82 (Bykov Yu.V., Khannanova A.N., Bekker R.A. V mire nauchnykh otkrytiy. 2016. V. 79. №, рр. 60–82).
Allison D.B., Mackell J.A., McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia // Psychiatric Services. 2003. Т. 54. №. 4. С. 565–567.
Aruna A.S., Murungi J. H. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient // Annals of Pharmacotherapy. 2005. Т. 39. №. 6. С. 1131–1135.
Baandrup L., Fagerlund B., Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo // European archives of psychiatry and clinical neuroscience. 2017. Т. 267. №. 2. С. 163–171.
Banach M. et al. Melatonin in experimental seizures and epilepsy // Pharmacological Reports. 2011. Т. 63. №. 1. С. 1–11.
Boguszewska A., Pasternak K. Melatonin and bio-elements // Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. 2004. Т. 17. №. 101. С. 528–529.
Butun I. et al. The effects of different doses of melatonin on lipid peroxidation in diet-induced hypercholesterolemic rats // Bratislavske lekarske listy. 2013. Т. 114. №. 3. С. 129–132.
Cardinali D.P. et al. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin // Neuro Endocrinol Lett. 2011. Т. 32. №. 5. С. 588–606.
Carta M.G. et al. Tardive dyskinesia: review of the literature // La Clinica terapeutica. 2004. Т. 155. №. 4. С. 127–133.
Castro F. et al. Effectiveness of melatonin in tardive dyskinesia // Investigacion clinica. 2011. Т. 52. №. 3. С. 252–260.
Cho C. H., Lee H. J. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence // Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013. Т. 46. С. 207–213.
Correll C. U. et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents // Jama. 2009. Т. 302. №. 16. С. 1765–1773.
Cuesta S. et al. Melatonin can improve insulin resistance and aging-induced pancreas alterations in senescence-accelerated prone male mice (SAMP8) //Age. 2013. Т. 35. №. 3. С. 659–671.
Daniels S. R. et al. Overweight in children and adolescents //Circulation. 2005. Т. 111. №. 15. С. 1999–2012.
De Hert M. et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice // European Psychiatry. 2011. Т. 26. №. 3. С. 144–158.
De Hert M. et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care //World psychiatry. 2011. Т. 10. №. 1. С. 52–77.
Diez E.R. et al. A novel electrophysiologic effect of melatonin on ischemia/reperfusion-induced arrhythmias in isolated rat hearts // Journal of pineal research. 2009. Т. 46. №. 2. С. 155–160.
Divac N. et al. Second-generation antipsychotics and extrapyramidal adverse effects // BioMed research international. 2014. Т. 2014. С. 656–370.
Dodd S., S Fernandes B., M Dean O. Future directions for pharmacotherapies for treatment-resistant bipolar disorder //Current neuropharmacology. 2015. Т. 13. №. 5. С. 656–662.
Drago F. et al. Acute low doses of melatonin restore full sexual activity in impotent male rats // Brain research. 2000. Т. 878. №. 1. С. 98–104.
Esquifino A.I. et al. Melatonin effects on prolactin secretion in pituitary-grafted female rats // Journal of endocrinological investigation. 1989. Т. 12. №. 3. С. 171–176.
Findling R.L., Steiner H., Weller E.B. Use of antipsychotics in children and adolescents // The Journal of clinical psychiatry. 2005. Т. 66. С. 29–40.
Fontaine K.R. et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate //Psychiatry research. 2001. Т. 101. №. 3. С. 277–288.
Glazer W.M., Morgenstern H., Doucette J.T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications // The Journal of clinical psychiatry. 1993. Т. 54. №. 4. С. 133.
Giladi N., Shabtai H. Melatonin-induced withdrawal emergent dyskinesia and akathisia // Movement disorders. 1999. Т. 14. №. 2. С. 381–382.
Golmirzaei J. et al. Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects // Current pharmaceutical design. 2016. Т. 22. №. 5. С. 590–594.
Gothelf D. et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine // American Journal of Psychiatry. 2002. Т. 159. №. 6. С. 1055–1057.
Grad B.R., Rozencwaig R. The role of melatonin and serotonin in aging: update // Psychoneuroendocrinology. 1993. Т. 18. №. 4. С. 283–295.
Graham K.A. et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine // American Journal of Psychiatry. 2005. Т. 162. №. 9. С. 1744–1746.
Hansen M.V. et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial //Breast cancer research and treatment. 2014. Т. 145. №. 3. С. 683–695.
Heidrich J.P. et al. On-Line Analysis of Electrolytes in Extracorporeally Circulating Blood: Application of a Rat Model to Examine the Effect of a Single Pharmacological Dose of Melatonin on Electrolyte Levels in Blood // Clinical chemistry and laboratory medicine. 2000. Т. 38. №. 3. С. 215–220.
Howland R.H. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain // Journal of psychosocial nursing and mental health services. 2015. Т. 53. №. 6. С. 19–22.
Huang G., Fu Q., Xu J. Potential torsades de pointes triggered by hypokalemia related to olanzapine in a patient with implantable cardioverter-defibrillator //Journal of clinical psychopharmacology. 2014. Т. 34. №. 5. С. 651–652.
Jeste D.V. Tardive dyskinesia in older patients // The Journal of clinical psychiatry. 1999. Т. 61. С. 27–32.
Jeste D.V. Tardive dyskinesia rates with atypical antipsychotics in older adults // The Journal of clinical psychiatry. 2004. Т. 65. С. 21–24.
Jones P.B. et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) // Archives of general psychiatry. 2006. Т. 63. №. 10. С. 1079–1087.
Khasawneh F.T., Shankar G.S. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia // Cardiology Research and Practice. 2014. Т. 2014. С. 273060.
Kinon B.J. et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia // The Journal of clinical psychiatry. 2001. Т. 62. №. 2. С. 92.
Kleinberg D.L. et al. Prolactin levels and adverse events in patients treated with risperidone // Journal of clinical psychopharmacology. 1999. Т. 19. №. 1. С. 57–61.
Krill R.A., Kumra S. Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management // Adolescent health, medicine and therapeutics. 2014. Т. 5. С. 171.
Lai I.C. et al. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia // The World Journal of Biological Psychiatry. 2011. Т. 12. №. 2. С. 143–148.
Lett T.A. P. et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications // Molecular psychiatry. 2012. Т. 17. №. 3. С. 242.
Lieberman J.A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N Engl j Med. 2005. Т. 2005. №. 353. С. 1209–1223.
Lin Y.C. et al. Hypokalemia Following Rapid Titration of Quetiapine Treatment. Authors’ reply //The Journal of clinical psychiatry. 2008. Т. 69. №. 1. С. 165–166.
Lissoni P. et al. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia //Journal of endocrinological investigation. 1990. Т. 13. №. 2. С. 85–89.
Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia // CNS drugs. 2003. Т. 17. №. 1. С. 47–62.
Lohr J. B. et al. The clinical challenges of akathisia // CNS spectrums. 2015. Т. 20. №. S1. С. 1–16.
Maldonado M.D., Reiter R.J., Pérez-San-Gregorio M.A. Melatonin as a potential therapeutic agent in psychiatric illness // Human Psychopharmacology: Clinical and Experimental. 2009. Т. 24. №. 5. С. 391–400.
Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review // Schizophrenia research. 2004. Т. 70. №. 1. С. 1–17.
Milovanovic D.R. et al. Risperidone-associated hypocalcemia // American Journal of Psychiatry. 2010. Т. 167. №. 12. С. 1533–1534.
Modabbernia A. et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study // Journal of psychiatric research. 2014. Т. 53. С. 133–140.
Mohammadi M.R. R. et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial // Iranian journal of psychiatry. 2012. Т. 7. №. 2. С. 87–92.
Morera-Fumero A.L., Abreu-Gonzalez P. Role of melatonin in schizophrenia //International journal of molecular sciences. 2013. Т. 14. №. 5. С. 9037–9050.
Mostafavi A. et al. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial // Acta Medica Iranica. 2014. Т. 52. №. 10. С. 734.
Mostafavi S.A. et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement? //Iranian journal of psychiatry. 2012. Т. 7. №. 3. С. 114.
Naidu P.S. et al. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia // Pharmacology Biochemistry and Behavior. 2003. Т. 74. №. 3. С. 641–648.
Nelson L.A., McGuire J.M., Hausafus S.N. Melatonin for the treatment of tardive dyskinesia // Annals of Pharmacotherapy. 2003. Т. 37. №. 7–8. С. 1128–1131.
Nelson R.J., Demas G.E. Role of melatonin in mediating seasonal energetic and immunologic adaptations // Brain research bulletin. 1997. Т. 44. №. 4. С. 423–430.
Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications // The Canadian Journal of Psychiatry. 2006. Т. 51. №. 8. С. 480–491.
Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus // Endocrine. 2005. Т. 27. №. 2. С. 131.
Pacia S.V., Devinsky O. Clozapine-related seizures Experience with 5,629 patients // Neurology. 1994. Т. 44. №. 12. С. 2247–2247.
Peschke D., Peschke E., Mess B. Circannual rhythm and increase of body weight and food intake in the young Wistar rat following pinealectomy and ganglionectomy // Neuroendocrinology Letters. 1987. Т. 9. №. 5. С. 321–327.
Pringsheim T. et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth // Paediatrics & child health. 2011. Т. 16. №. 9. С. 590–598.
Rasmussen D.D. et al. Daily melatonin administration at middle age suppresses male rate visceral fat, plasma leptin, and plasma insulin to youthful levels //Endocrinology. 1999. Т. 140. №. 2. С. 1009–1012.
Raviña T., Raviña P., Gutierrez J. Acquired long QT syndrome: Risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I // International journal of cardiology. 2007. Т. 116. №. 3. С. 416–420.
Ray W.A. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death // New England Journal of Medicine. 2009. Т. 360. №. 3. С. 225–235.
Reiter R.J. et al. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression // Annals of medicine. 2012. Т. 44. №. 6. С. 564–577.
Romo-Nava F. et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial // Bipolar disorders. 2014. Т. 16. №. 4. С. 410–421.
Sandyk R. Tardive dyskinesia in bipolar disorders: Possible role of pineal melatonin // International journal of neuroscience. 1990. Т. 52. №. 3–4. С. 233–238.
Sandyk R. The relationship of pineal calcification to subtypes of tardive dyskinesia in bipolar patients // International Journal of Neuroscience. 1990. Т. 54. №. 3–4. С. 307–313.
Sandyk R., Awerbuch G.I. The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis //International journal of neuroscience. 1994. Т. 76. №. 1–2. С. 81–86.
Sandyk R., Kay S.R. The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette’s syndrome //International journal of neuroscience. 1991. Т. 58. №. 3-4. С. 215–247.
Scarff J.R., Casey D.A. Newer oral atypical antipsychotic agents: a review //Pharmacy and Therapeutics. 2011. Т. 36. №. 12. С. 832.
Scheuer C. et al. Effect of topical application of melatonin cream 12.5% on cognitive parameters: A randomized, placebo-controlled, double-blind crossover study in healthy volunteers // Journal of Dermatological Treatment. 2016. Т. 27. №. 6. С. 488–494.
Shamir E. et al. Is melatonin treatment effective for tardive dyskinesia? // The Journal of clinical psychiatry. 2000. Т. 61. №. 8. С. 556–558.
Shamir E. et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study // Archives of general psychiatry. 2001. Т. 58. №. 11. С. 1049–1052.
Shulman M. et al. Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach // Journal of multidisciplinary healthcare. 2014. Т. 7. С. 489.
Stahl S.M. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013.
Stevenson R.J. Amisulpride overdose: suggested management of prolonged QTc // Emergency Medicine Journal. 2010. Т. 27. №. 7. С. 565–565.
Tavukçu H.H. et al. Melatonin and tadalafil treatment improves erectile dysfunction after spinal cord injury in rats // Clinical and Experimental Pharmacology and Physiology. 2014. Т. 41. №. 4. С. 309–316.
Tordjman S. et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives //International journal of molecular sciences. 2013. Т. 14. №. 10. С. 20508–20542.
Trotti L.M., Karroum E.G. Melatonin for sleep disorders in patients with neurodegenerative diseases // Current neurology and neuroscience reports. 2016. Т. 16. №. 7. С. 63.
Túnez I. et al. Effect of melatonin on hyperlipidemic nephropathy under constant light exposure // Journal of physiology and biochemistry. 2002. Т. 58. №. 2. С. 109–114.
Vazan R., Ravingerova T. Protective effect of melatonin against myocardial injury induced by epinephrine // Journal of physiology and biochemistry. 2015. Т. 71. №. 1. С. 43–49.
Vermeeren A., Coenen A.M. Effects of the use of hypnotics on cognition //Progress in brain research. 2011. Т. 190. С. 89–103.
Vilhelmsson A. Depression and Antidepressants: A Nordic Perspective //Frontiers in Public Health. 2013. Т. 1. С. 30.
Vinogradova I., Anisimov V. Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimens // Biogerontology. 2013. Т. 14. №. 4. С. 401–409.
Wang H.R., Woo Y.S., Bahk W.M. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review //International clinical psychopharmacology. 2016. Т. 31. №. 6. С. 301–306.
Werneke U., Turner T., Priebe S. Complementary medicines in psychiatry //The British Journal of Psychiatry. 2006. Т. 188. №. 2. С. 109–121.
Wirshing D.A. et al. Novel antipsychotics: comparison of weight gain liabilities // The Journal of clinical psychiatry. 1999. Т. 60. №. 6. С. 358.
Yildiz M. et al. State of the art psychopharmacological treatment options in seasonal affective disorder // Psychiatria Danubina. 2016. Т. 28. №. 1. С. 1–29.
Zisapel N. Melatonindopamine interactions: from basic neurochemistry to a clinical setting // Cellular and molecular neurobiology. 2001. Т. 21. №. 6. С. 605–616.
DOI: https://doi.org/10.12731/wsd-2017-4-174-204
Ссылки
- На текущий момент ссылки отсутствуют.
(c) 2017 Roman Aleksandrovich Bekker, Angelina Nailevna Hannanova, Yuriy Vitalevich Bykov
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
ISSN 2658-6649 (print)
ISSN 2658-6657 (online)